Must be in first or second recurrence (including this recurrence)
Recurrence must be confirmed by diagnostic biopsy with local pathology review or contrast-enhanced MRI. If first recurrence of GBM is documented by MRI, an interval of at least 12 weeks after the end of prior radiation therapy is required unless there is either: i) histopathologic confirmation of recurrent tumor, or ii) new enhancement on MRI outside of the radiotherapy treatment field
Must have had progression or recurrence of urothelial cancer during or following receipt of most recent therapy.
In both the above cases, the lesion considered at highest risk for recurrence based on the investigator's discretion will be used for eligibility determination
If primary disease in the thoracic cavity was previously treated with local therapy in the form of surgery, any local/regional disease recurrence should be technically treatable with SBRT or hypofractionated radiation after induction systemic therapy.
Pathologic evidence of active primary disease or local/regional breast tumor recurrence at the time of registration;
Patient must either have recurrence of CNS GCT or should be refractory to initial therapy
Patients must be in first recurrence of glioblastoma following radiation therapy and temozolomide
Patient has had more than one recurrence or progression of their tumors.
Patients must have measurable or non-measurable (evaluable) disease recurrence\r\n* Recurrence must be documented based on a combination of clinical and imaging parameters, consistent with routine clinical practice, with or without histologic confirmation\r\n* Patients may have had any number of relapses and be eligible for the study
Has documented disease-free interval (DFI) > 8 weeks after completion of initial therapy; DFI is from the time of completion of initial treatment (from date last known disease-free at end of initial treatment) to the diagnosis of local or loco-regional recurrence
Subjects with any recurrence (first, second, third, etc recurrence) will be able to be enrolled
Patients who have PSA recurrence after local salvage therapy may participate in this study
Patients may not have therapy for this recurrence (including radiation)
Endometrial cancer\r\n* Patients at a higher risk of recurrence (because of either grade, myometrial invasion, lymphatic vascular space invasion, tumor size, lymph node status, tumor extension, presence or absence of surgical staging)\r\n* Patients who have suffered a recurrence at the vaginal cuff\r\n* Patients who are unable to undergo surgery and must have treatment for an inoperable primary endometrial cancer
If first recurrence of GBM is documented by MRI, an interval of at least 12 weeks after the end of prior radiation therapy is required unless there is either:\r\n* histopathologic confirmation of recurrent tumor, or\r\n* new enhancement on MRI outside of the radiotherapy treatment field
Patients must be in first recurrence of glioblastoma following radiation therapy and temozolomide
Second primary malignancy within the last 5 years, unless treated definitively and with low risk of recurrence in the judgment of the treating investigator
Patients with persistent disease and local recurrence must not be amenable to local treatment.
Patients with concurrent second malignancy. Persons with previous malignancies effectively treated and not requiring treatment for >24 months are eligible, provided there is unambiguous documentation that current local recurrence or metastatic site represents recurrence of the primary breast malignancy.
BIOCHEMICAL RECURRENCE COHORT
Biochemical recurrence within one year of completion of radiotherapy
Histologic or cytologic diagnosis of NSCLC who have received previous intrathoracic radiation therapy with definitive intent and have a tumor recurrence in or near the prior irradiation fields; re-biopsy of the recurrence is not required and is left to the discretion of the treating physician, although every effort should be made to confirm recurrence pathologically
Patients with concurrent second malignancy. Persons with previous malignancies effectively treated and not requiring treatment for >24 months are eligible, provided there is unambiguous documentation that current local recurrence or metastatic site represents recurrence of the primary breast malignancy.
Any patient eligible for internal implantation without MR guidance will be considered eligible for this protocol; standard criteria for internal implantation include:\r\n* Carcinoma of the cervix: stage I-IVA or vaginal recurrence\r\n* Carcinoma of the uterus: stage IIIB (vaginal involvement), inoperable, or vaginal recurrence\r\n* Carcinoma of the vagina: stage I-IVA or vaginal recurrence\r\n* Carcinoma of the vulva: stage I-IVA or recurrence\r\n* Carcinoma of the urethra based on treating physician’s discretion
Patients must have local or metastatic recurrence of IBC after prior surgery
Prior therapy with gamma knife or other focal high-dose radiotherapy is allowed, but the patient must have subsequent histologic documentation of recurrence, unless the recurrence occurs remote from the treated site
Prior therapy with gamma knife or other focal high-dose radiation is allowed, but at least 2 weeks must have elapsed from the time of treatment, and the patient must have subsequent histologic documentation of recurrence, unless the recurrence is a new lesion outside the irradiated field.
Patient must have imaging findings within the last 3 months consistent with recurrent disease in the brain; pathologic diagnosis of recurrence is not required
Recurrence of glioblastoma (GBM) since completion of most recent therapy; recurrence must be documented by diagnostic biopsy or contrast enhanced magnetic resonance imaging (MRI) performed within 21 days prior to entering the study per Response Assessment in Neuro-Oncology (RANO) criteria
Patients with GBM or anaplastic astrocytoma must be at first or second recurrence (including this recurrence) or have progressed following initial definitive multimodal therapy with surgery, temozolomide, and radiation (confirmed by diagnostic biopsy with local pathology review or contrast-enhanced magnetic resonance imaging [MRI]). If first recurrence is documented by MRI, an interval of at least 12 weeks after the end of prior radiation therapy is required, unless there is either histopathologic confirmation of recurrent tumor or new enhancement on MRI outside the radiotherapy treatment field.
There must be an interval of at least 12 weeks from the completion of radiotherapy to study registration except if there is unequivocal evidence for tumor recurrence per Response Assessment in Neuro-Oncology (RANO) criteria; when the interval is less than 12 weeks from the completion of radiotherapy, the use of positron emission tomography (PET) scan is allowed to differentiate between evidence of tumor recurrence and pseudoprogression
Documentation of recurrence/progression/residual disease following prior therapy
Patients who have failed previous hemi-thoracic platinum therapy will be ineligible (“failed” is having disease recurrence =< 3 months)
Patients with a history of non-breast malignancies are eligible as long as they have not received prior radiotherapy to the thoracic region, and have a greater than 2 year interval without evidence of recurrence
Progression or recurrence of breast cancer while on or after aromatase inhibitor treatment
Patient must either have recurrence of ICGCT or should be refractory to initial therapy
Patients with histologically confirmed, non-central nervous system (CNS) solid malignancies who have been previously radiated and have a tumor recurrence in or near prior radiation fields; re-biopsy of the recurrence is not required and left to the discretion of the treating physician, although every effort should be made to confirm recurrence
For tumors other than DSRCT, patients must have a history of tumor progression or recurrence or failure to achieve complete response with standard therapy or < 20% chance of long term disease-free survival
Must have a history of tumor progression or recurrence or failure to achieve complete response with standard therapy
If subjects have not passed an interval of at least 6 months, they may still be eligible if they meet the following criteria: convincing histologic evidence of disease recurrence which is not thought to predominantly represent radionecrosis, standard focal external beam radiation therapy (EBRT) treatment with acceptable doses to tumor and normal tissue which suggest re-irradiation is feasible; these cases of early recurrence must be reviewed and approved by the study PI for enrollment into the trial
No prior malignancy is allowed except for cancers that have been definitively treated with a risk of recurrence of < 30% based on the treating oncologists assessment
Repeat surgery for recurrence of disease
Subjects with recurrence must have a documented complete response upon completion of initial definitive therapy
Subjects who have a solitary central pelvic recurrence which can be curatively resected
Patients with concurrent local and pulmonary recurrence at the time of enrollment; note: patients who had local recurrence previously that has been treated and now present with an isolated pulmonary recurrence and meet the surgical resection criteria stated above will be eligible
An interval of at least 6 months after the end of prior radiation therapy is required unless there is a new recurrence outside of the previous radiotherapy treatment field
Evidence of local recurrence in the prostate bed
Arm 1 patients must be in first recurrence of glioblastoma following radiation therapy and temozolomide
Recurrence score (RS) by Oncotype DX must be =< 25
For patients with Grade IV GBM, recurrent disease at the time of the first or second recurrence or progression. For patients with Grade III anaplastic gliomas, recurrent disease at the time of at least a first recurrence but no more than a fourth recurrence or progression
A cancer diagnosed and definitively treated ? 5 years before randomization with no subsequent evidence of recurrence
Patient has recurrence or progression of disease during or after AI therapy (i.e. letrozole, anastrozole, exemestane).
Clinical and radiologic assessments that are negative for local or regional recurrence of disease or metastatic disease at the time of study entry, including
Prior therapy with gamma knife or other focal high-dose radiotherapy is allowed, but the patient must have subsequent histologic documentation of recurrence, unless the recurrence is a new lesion outside the irradiated field.
Surgery must have confirmed the recurrence
Non-measurable disease: includes patients with symptomatic ascites or pleural effusions, lesions that do not meet RECIST criteria or biopsy proven recurrence; patients with clinically evident non-measurable disease must have either an elevated CA125 or histological confirmation of recurrence
Experienced progression/recurrence of disease during or subsequent to the most recent anti-cancer regimen.
Patient may have been operated for recurrence. If operated: residual and measurable disease after surgery is required;
Radiologic/objective evidence of recurrence or progression to the most recent systemic therapy for breast cancer
Recurrence while on, or within 12 months of end of adjuvant treatment with letrozole or anastrozole, or
Previous chemotherapy for local recurrence is allowed but must have been discontinued at least 4 weeks before receiving the study drug and the patient must have recovered from acute adverse effects
disease recurrence either must occur within 12 months of the most recent intravesical therapy of any kind, OR
An interval of at least 6 months after the end of prior radiation therapy is required unless there is a new recurrence outside of the previous radiotherapy treatment field
History of local and/or regional and/or distant melanoma recurrence
Greater than 12 weeks from radiotherapy, to minimize the potential for MRI changes related to radiation necrosis that might be misdiagnosed as pseudoprogression of disease, unless the recurrence is a new lesion, outside the primary radiation field or the patient fulfills criteria for early progressive disease by RANO ((Wen et al., 2010); Appendix C).
Prior therapy with gamma knife or other focal high-dose radiation is allowed, but at least 2 weeks must have elapsed from the time of treatment, and the patient must have subsequent post-radiotherapy histologic documentation of recurrence in the irradiated field, unless the recurrence is a new lesion outside the irradiated field.
Patients with previous solid and hematologic tumors, that have been treated with no evidence of recurrence within the last 5 years, are permitted.
History of other carcinoma =< 3 years; exception: if risk of recurrence is known to be under 5% at time of randomization
Patients may sign screening consent during recurrence or at time of remission if they can start vaccine therapy within 4 months of completing chemotherapy
Recurrence may occur after any treatment: recurrence after whole-brain radiation, stereotactic radiosurgery, surgical resection, systemic chemotherapy are all acceptable
Progression or recurrence after treatment
There has been no evidence of recurrence of any prior malignancies for at least FIVE years (except for successfully treated cervical or non-melanoma skin cancer with no evidence of recurrence), and
Histologically or cytologically confirmed non-keratinizing nasopharyngeal carcinoma (NPC) that has recurred at locoregional and/or distant sites; NOTE: patients with local recurrence at the bony skull-base as the only site of index disease are excluded; patients with locoregional recurrence without distant metastases must have undergone radical radiotherapy previously
Baseline Oncotype Dx recurrence score =< 25
Lack of archival specimens from the time of primary or recurrence diagnosis
Subject has refractory disease or developed recurrence after therapy with a BCR PI
Patients who have failed previous intraperitoneal platinum therapy will be ineligible (“failed” is having disease recurrence =< 3 months)
Stratum 2: patients must have received radiation therapy, which may include gamma knife or phosphorus-32 (P32)\r\n* More than 6 months from the time of enrollment if the recurrence is predominantly solid\r\n* More than 12 months from the time of enrollment if the recurrence is predominantly cystic
There must be an interval of at least 12 weeks from the completion of radiotherapy to study registration except if there is unequivocal evidence for tumor recurrence per Response Assessment in Neuro-Oncology (RANO) criteria; when the interval is less than 12 weeks from the completion of radiotherapy, the use of positron emission tomography (PET) scan is allowed to differentiate between unequivocal evidence of tumor recurrence and pseudo progression
International Association for the Study of Lung Cancer (IASLC) version 7, stage IV disease; or recurrence after prior surgery or radiotherapy
Patients who develop a recurrence or progression (WHO criteria) of an MPNST in a previously radiated field may be enrolled if it has been at least 4 weeks since the last dose of radiation therapy
Patients must have pathologically confirmed recurrence at the time of catheter placement
Patients must have measurable or non-measurable (evaluable) disease recurrence\r\n* Recurrence must be documented based on a combination of clinical and imaging parameters, consistent with routine clinical practice, with or without histologic confirmation\r\n* Patients may have had any number of relapses and be eligible for the study
Any patient eligible for internal implantation without MR guidance will be considered eligible for this protocol; standard criteria for internal implantation include:\r\n* Carcinoma of the cervix: stage I-IVA or vaginal recurrence\r\n* Carcinoma of the uterus: stage IIIB (vaginal involvement), inoperable, or vaginal recurrence\r\n* Carcinoma of the vagina: stage I-IVA or vaginal recurrence\r\n* Carcinoma of the vulva: stage I-IVA or recurrence\r\n* Carcinoma of the urethra/bladder
No other signs of clinical recurrence or dissemination of prostate cancer as defined by normal CT-scan or MRI of the pelvis without local recurrence, and bone scan negative for metastases, and chest X-ray negative for metastases; prostascint scans will not be used to assess disease prior to study entry
Positive clinical and radiologic assessments for local or regional recurrence of disease at the time of study entry.
Patients must have shown unequivocal evidence for tumor recurrence or progression by MRI scan and should have failed radiation therapy. The scan done prior to study entry documenting progression will be reviewed by the treating physician to document changes in tumor dimension to confirm recurrence. Patients with prior therapy that included interstitial brachytherapy or stereotactic radiosurgery must have confirmation of true progressive disease rather than radiation necrosis.
Patients who have had a previous malignancy unless they are deemed by their treating physicians to be at low risk for recurrence
Have received at least one any prior treatment for local recurrence or metastatic disease and have relapsed
Patients with histologically or cytologically confirmed locally advanced breast cancer that is refractory to chemotherapy or other therapeutic agents or with a history of breast cancer with new evidence of a local recurrence (defined as a chest wall or breast recurrence and/or nodal recurrence); the diagnosis will be made based on clinical and pathologic features
First recurrence (based on radiological or histological evidence of recurrence)
Second or subsequent recurrence
History of cancer (other than GBM) within the past 2 years that has metastatic or local recurrence potential and could negatively impact survival and/or potentially confound tumor response assessments within this study.
Has the subject had histologically proven HGG with recurrence or progression following initial definitive therapy(s) such as surgery with or without adjuvant radiation therapy and/or chemotherapy (confirmed by diagnostic biopsy or contrast-enhanced MRI and evaluable by Macdonald criteria)? Note, if first recurrence of HGG is documented by MRI, an interval of at least 12 weeks after the end of prior radiation therapy is required unless there is either: i) histopathologic confirmation of recurrent tumor, or ii) new enhancement on MRI outside of the radiotherapy treatment field.
Subjects that have had more than one disease recurrence
Refractory disease on most recent therapy, or disease recurrence following remission on most recent therapy;
Tumor progression or recurrence within 6 months of last dose of platinum therapy that was used to treat metastatic, persistent or recurrent cervical cancer
more than 2 recurrences including present recurrence
Histologically documented recurrent/metastatic adenocarcinoma of the breast with a recurrence on the chest wall (or its overlying skin):
The recurrence to be treated needs to be the 1st or 2nd recurrence of the AG or GBM
Patients may have had treatment (including radiotherapy) for any number of relapses prior to this recurrence
Other than surgery, patients may not have therapy for this recurrence (including radiation); supportive care such as steroids or anti-epileptics does not constitute treatment of recurrence
Patient had recurrence of osteosarcoma, localized to the lungs, had complete surgical removal of all lung nodules are eligible for enrollment.
Patient had recurrence of osteosarcoma in the lung following standard therapy including: adriamycin, cisplatin, ifosfamide and methotrexate.
Within 0-5 years post-active treatment for initial diagnosis or recurrence
Evidence of breast cancer recurrence or metastasis
Current recurrence of their breast cancer (BC) (local or distant)
Have not had recurrence
Participants who develop treatment complications or disease recurrence after being enrolled in the study may continue to participate if they are able to do so
Have not had a cancer recurrence
Malignant tumors other than HNC within the last 5 years, unless treated definitively and with low risk of recurrence in the judgment of the treating investigator
No local or distant recurrence of their breast cancer
Evidence of active progression of disease or recurrence
Participants who develop treatment complications or disease recurrence after being enrolled in the study may continue to participate if they are able to do so
Have not experienced a cancer recurrence, and
No evidence of recurrence
Patients with local disease recurrence would be excluded from the trial
May be receiving maintenance therapy that has a goal of prevention of recurrence but there should be no expectations for further active treatment
Evidence of biochemical recurrence
Evidence of tumor recurrence/progression by MRI (RANO criteria) post standard initial therapy.
Other completely resected stage 1 solid tumor with low risk for recurrence
Known recurrence of breast cancer (local, regional or distant) at any time prior to study entry.
Patient must not have planned treatment with immunotherapies (vaccines, checkpoint inhibitors, T-cells); if the patient’s most recent recurrence occurs while on immunotherapy, this must be judged as true recurrence using Immunotherapy Response Assessment in Neuro-Oncology (iRANO) criteria
Sufficient tumor specimen thought to be available to meet the minimum requirements for profiling from diagnosis or progression/recurrence; OR
If prior treatment with radiation or ablative therapy, evidence of recurrence outside the confines of prior treated site(s) is needed.
Patients presenting with a CNS tumor presumed to be resectable and are at risk for local recurrence on pre-operative assessment
Evidence of prostate cancer recurrence (biochemical relapse by the Phoenix definition, enlarging palpable prostatic abnormality, imaging evidence strongly suggestive of local failure)
Patients who initiated androgen deprivation therapy or other systemic therapy (chemotherapy, immunotherapy, targeted therapy) for PSA recurrence; nutritional supplements used for treatment of PSA recurrence will be allowed
Participants will be excluded if they have a recurrence that requires anti-cancer treatment
Evidence of biochemical recurrence
The patient must be at low- or low-intermediate risk for disease recurrence and progression according to the EAU guidelines
